A Retrospective Study Assessing the Efficacy of Apatinib in Patients with Advanced Chemo-Refractory Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2017 New trial record